X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Iomab-B (apamistamab-I-131) is a murine monoclonal antibody in conjugation with iodine-131 (131I), which is being evaluated for the treatment of relapsed or refractory (r/r) acute myeloid leukemia.
Lead Product(s): Apamistamab-I-131
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The funding will support company's clinical collaboration with MSK to study Iomab-ACT (apamistamab-I-131), its CD45-targeting radiotherapeutic, for targeted conditioning to achieve lymphodepletion therapy prior to administration of a CD19-targeted CAR-T cell therapy.
Lead Product(s): Apamistamab-I-131
Therapeutic Area: Oncology Product Name: Iomab-ACT
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2023
Details:
Iomab-B links apamistamab to the radioisotope iodine-131 and once attached to its target cells emits energy that travels a relatively long distance, destroying a patient's cancer cells and ablating their bone marrow. It is being developed for AML.
Lead Product(s): Apamistamab-I-131
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2023
Details:
Iomab-B links apamistamab to the radioisotope iodine-131 and once attached to its target cells emits energy that travels a relatively long distance, destroying a patient's cancer cells and ablating their bone marrow.
Lead Product(s): Apamistamab-I-131
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Under the terms of the CRADA, the NCI will serve as sponsor for any clinical trials mutually approved by both parties to study Actimab-A (lintuzumab-Ac225) while Actinium will be responsible for supplying and distributing Actimab-A.
Lead Product(s): Lintuzumab-ac225,Spironolactone
Therapeutic Area: Oncology Product Name: Actimab-A
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2023
Details:
Lomab-B (apamistamab-I-131) is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously and rapidly depleting blood cancer, immune and bone marrow stem cells that uniquely express CD45.
Lead Product(s): Apamistamab-I-131,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
Actimab-A (lintuzumab-Ac-225) is an Actinium-225 based antibody radiation conjugate targeting CD33, a validated target that is expressed in virtually all patients with AML. Actimab-A due to its radiation modality is agnostic to cytogenetics.
Lead Product(s): Lintuzumab-Ac225,Cladribine,Cytarabine
Therapeutic Area: Oncology Product Name: Actimab-A
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Columbia University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2022
Details:
Patients on study of Actimab-A (Lintuzumab-Ac225) received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of patients having a TP53 mutation.
Lead Product(s): Lintuzumab-Ac225,Cladribine,Mitoxantrone
Therapeutic Area: Oncology Product Name: Actimab-A
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Iomab-B (apamistamab-I-131) is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously and rapidly depleting blood cancer, immune and bone marrow stem cells that uniquely express CD45.
Lead Product(s): Apamistamab-I-131,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Iomab-B (apamistamab-I-131) via the monoclonal antibody apamistamab, targets CD45, an antigen widely expressed on all types of blood cancer cells and immune cells including bone marrow progenitor stems cells.
Lead Product(s): Apamistamab-I-131,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Iomab-B
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
